Perspective Therapeutics’ (CATX) “Outperform” Rating Reiterated at Wedbush

Wedbush reiterated their outperform rating on shares of Perspective Therapeutics (NYSEAMERICAN:CATX) in a report issued on Tuesday,Benzinga reports. The brokerage currently has a $11.00 target price on the stock.

Other research analysts also recently issued reports about the stock. Bank of America reduced their price objective on shares of Perspective Therapeutics from $6.00 to $5.00 and set a “neutral” rating on the stock in a research note on Friday, August 14th. Piper Sandler cut their target price on shares of Perspective Therapeutics from $16.00 to $14.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 11th. BTIG Research restated a “buy” rating on shares of Perspective Therapeutics in a research note on Friday, July 24th. Finally, BMO Capital Markets set a $11.00 price target on shares of Perspective Therapeutics and gave the stock an “outperform” rating in a research report on Tuesday, August 18th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $11.50.

Perspective Therapeutics Stock Performance

CATX stock opened at $2.88 on Tuesday. The stock’s 50 day moving average is $3.04 and its two-hundred day moving average is $3.66. Perspective Therapeutics has a 52-week low of $1.96 and a 52-week high of $6.16.

Perspective Therapeutics (NYSEAMERICAN:CATX) last released its quarterly earnings results on Monday, August 10th. The company reported ($0.22) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.03. The business had revenue of $0.08 million during the quarter, compared to the consensus estimate of $0.09 million. Perspective Therapeutics had a negative net margin of 28,467.97% and a negative return on equity of 41.92%. As a group, equities research analysts predict that Perspective Therapeutics will post -0.98 EPS for the current fiscal year.

Hedge Funds Weigh In On Perspective Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the business. Commodore Capital LP acquired a new stake in Perspective Therapeutics during the first quarter worth about $26,424,000. Avidity Partners Management LP boosted its stake in Perspective Therapeutics by 88.4% in the first quarter. Avidity Partners Management LP now owns 6,049,999 shares of the company’s stock valued at $25,228,000 after acquiring an additional 2,839,266 shares during the period. Affinity Asset Advisors LLC grew its holdings in shares of Perspective Therapeutics by 954.9% during the first quarter. Affinity Asset Advisors LLC now owns 3,164,582 shares of the company’s stock valued at $13,196,000 after purchasing an additional 2,864,582 shares during the last quarter. Spruce Street Capital LP bought a new position in shares of Perspective Therapeutics during the first quarter valued at approximately $10,955,000. Finally, Yu Fan bought a new position in shares of Perspective Therapeutics during the first quarter valued at approximately $4,401,000. Institutional investors and hedge funds own 54.66% of the company’s stock.

About Perspective Therapeutics

Perspective Therapeutics, Inc is a clinical-stage biotechnology company developing precision-targeted radiopharmaceuticals for the treatment of cancer. The company focuses on therapies that combine tumor-targeting molecules with radioactive isotopes designed to deliver radiation directly to malignant cells while limiting exposure to surrounding healthy tissue.

Perspective Therapeutics’ proprietary VMT platform is intended to support the development of both therapeutic and diagnostic radiopharmaceuticals.